Treatment of latent tuberculosis infection: An update
- PMID: 20409026
- DOI: 10.1111/j.1440-1843.2010.01751.x
Treatment of latent tuberculosis infection: An update
Abstract
Isoniazid (INH) has been the mainstay of treatment of latent tuberculosis infection for almost 50 years. The currently recommended preferred regimen is 9 months daily self-administered INH (9H); this has efficacy of more than 90% if completed properly. Unfortunately, INH is associated with serious adverse events, including hepatotoxicity. Although risk factors for this complication are well established, allowing for better selection of candidates for therapy, this complication still occurs, and is occasionally fatal. Hence close follow up of patients is necessary, increasing the cost and complexity of treatment. This problem, plus the lengthy duration, results in poor acceptance by patients and providers, and poor adherence by patients. As a result, many preventable cases of tuberculosis continue to occur, and the public health impact of latent tuberculosis infection treatment is suboptimal. These problems have spurred interest in finding shorter, safer and cheaper alternative regimens, with similar efficacy. Of the many regimens that have been examined, 2 months of rifampin and pyrazinamide has excellent efficacy-in experimental studies in mice and randomized trials, largely in HIV-infected persons. However, while the safety of 2 months of rifampin and pyrazinamide appears acceptable in HIV-infected persons and children, in non-HIV-infected adults this regimen is associated with an unacceptably high rate of severe liver toxicity. Three to four months of INH and rifampin has had equivalent effectiveness as 6 months INH in several randomized trials. However, completion of therapy and toxicity has been the same as with INH-possibly because two drugs are taken rather than one. The fourth commonly studied regimen is 4 months rifampin. This has been found to have significantly better completion than 9H, with significantly less toxicity, especially hepatotoxicity. However, only one trial has evaluated efficacy and effectiveness of mono-rifampin therapy. In this trial, 3 months rifampin had somewhat better efficacy than either 3 months of isoniazid and rifampin (3HR) or 6 months isoniazid. Two large scale trials are ongoing; one is comparing efficacy and effectiveness of 9H with 4 months rifampin (both daily and self-administered), while the second, which is nearing completion, compares daily self-administered 9H with 3 months directly observed once weekly INH combined with rifapentine. The results of these two trials will likely shape future recommendations substantially.
Similar articles
-
A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.Pharmacoepidemiol Drug Saf. 2018 Jun;27(6):557-566. doi: 10.1002/pds.4423. Epub 2018 Mar 23. Pharmacoepidemiol Drug Saf. 2018. PMID: 29573031
-
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.Evid Based Child Health. 2014 Mar;9(1):169-294. doi: 10.1002/ebch.1962. Evid Based Child Health. 2014. PMID: 25404581
-
Treatment of latent tuberculosis infection.Ther Adv Respir Dis. 2013 Dec;7(6):351-6. doi: 10.1177/1753465813503028. Epub 2013 Sep 20. Ther Adv Respir Dis. 2013. PMID: 24056289 Review.
-
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.Cochrane Database Syst Rev. 2013 Jul 5;2013(7):CD007545. doi: 10.1002/14651858.CD007545.pub2. Cochrane Database Syst Rev. 2013. PMID: 23828580 Free PMC article. Review.
-
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.JAMA. 2000 Mar 15;283(11):1445-50. doi: 10.1001/jama.283.11.1445. JAMA. 2000. PMID: 10732934 Clinical Trial.
Cited by
-
Tuberculosis in United States-Bound Follow-to-Join Asylees, 2014-2019.Am J Trop Med Hyg. 2024 Mar 26;110(5):999-1005. doi: 10.4269/ajtmh.23-0233. Print 2024 May 1. Am J Trop Med Hyg. 2024. PMID: 38531107 Free PMC article.
-
Metabolic Rewiring of Mycobacterium tuberculosis upon Drug Treatment and Antibiotics Resistance.Metabolites. 2024 Jan 18;14(1):63. doi: 10.3390/metabo14010063. Metabolites. 2024. PMID: 38248866 Free PMC article. Review.
-
An effective vaccine is only the first step: the need to create and sustain demand for TB vaccines.Int J Tuberc Lung Dis. 2023 Oct 1;27(10):718-720. doi: 10.5588/ijtld.23.0365. Int J Tuberc Lung Dis. 2023. PMID: 37749838 Free PMC article. No abstract available.
-
Efficacy and Safety of Different Drug Regimens for Tuberculosis Preventive Treatment: A Systematic Review and Meta-Analysis.Cureus. 2023 Apr 26;15(4):e38182. doi: 10.7759/cureus.38182. eCollection 2023 Apr. Cureus. 2023. PMID: 37252497 Free PMC article. Review.
-
Latent Tuberculosis in India: An Overview.Cureus. 2023 Mar 2;15(3):e35706. doi: 10.7759/cureus.35706. eCollection 2023 Mar. Cureus. 2023. PMID: 37009383 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials